How to respond to a MAC appeal denial from your PBM

Maximum Allowable Cost — MAC — pricing is the single biggest reason independent pharmacies dispense generic medications below cost on specific claims. The MAC appeal process is the contractual and, in some states, statutory mechanism that lets pharmacies challenge below-cost MAC rates. Understanding how appeals work, and what to do when they fail, is essential for protecting margin on generic dispensing.

What MAC pricing actually is

Maximum Allowable Cost is a pricing benchmark that PBMs set for generic medications. Instead of reimbursing based on the medication's Average Wholesale Price (AWP) or Wholesale Acquisition Cost (WAC), the PBM sets a MAC rate — typically lower — that caps reimbursement for that specific NDC.

MAC rates are updated by the PBM on schedules that vary by agreement, sometimes as frequently as weekly. The updated rate applies to claims dispensed after the update, meaning a pharmacy that acquired inventory at one cost can receive reimbursement based on a rate set at a different cost — often lower than acquisition cost during periods of pricing volatility.

The appeal mechanism

Most PBM provider manuals specify an appeal process for MAC rates that result in below-cost reimbursement. The pharmacy submits documentation — typically a current invoice from an authorized wholesaler showing the actual acquisition cost — and requests that the MAC rate be adjusted to cover the cost.

When the appeal is accepted, the PBM either raises the MAC rate for that medication or provides a supplemental payment on the specific affected claims. When the appeal is denied, the pharmacy's reimbursement on the affected claims stands at the below-cost rate.

The appeal window is generally short. Most PBMs specify 14 to 21 days from the claim date, though some provider manuals allow longer. Missing the appeal window forecloses the remedy for those claims.

The 14-state protection framework

As of 2026, 14 states have enacted laws requiring PBMs to maintain transparent MAC methodology and provide appeal processes with specific minimum standards. The states vary, but the common features include: mandatory disclosure of the sources used to set MAC rates, required acceptance of invoices from authorized wholesalers as appeal documentation, mandatory PBM response within specified time windows, and in some states, mandatory MAC adjustment when a successful appeal demonstrates below-cost reimbursement.

If you operate in one of these states, your appeal rights are substantially stronger than in non-protection states. The state laws override contract provisions that would otherwise limit appeals. If you are not sure whether your state has MAC appeal protections, your state pharmacy association is the fastest source — most maintain current reference material.

What a successful appeal looks like

A complete MAC appeal submission typically includes: the claim number or claim date being appealed, the NDC and medication details, a current wholesale invoice showing the actual acquisition cost during the relevant period, and a brief narrative explaining that the MAC reimbursement falls below acquisition cost.

The documentation standard matters. A simple email stating that reimbursement is below cost is not sufficient. The invoice must be from an authorized source, must clearly show the specific NDC and quantity, and must be dated within the period relevant to the claim.

For medications purchased from secondary wholesalers or through alternative sourcing, be prepared to provide additional documentation showing that the source was authorized and that the pricing was the best reasonably available. Appeals involving non-primary-wholesaler acquisitions are denied more frequently than those involving primary wholesaler purchases.

When appeals fail

Appeal denials fall into three categories. Documentation denials — where the PBM determines that the submitted documentation does not satisfy requirements. Methodology denials — where the PBM applies its MAC methodology and concludes the rate is appropriate even when below the pharmacy's acquisition cost. And policy denials — where the PBM determines that the specific claim or medication falls outside the appeal process.

For documentation denials, the remedy is usually additional documentation. Request a specific explanation of the deficiency, provide whatever is missing, and resubmit within any remaining appeal window.

For methodology denials, the options depend on whether you are in a state with MAC protection laws. In protection states, the state regulator or pharmacy board can review the PBM's methodology and compel adjustment if the methodology violates state law. In non-protection states, the appeal is generally the last internal remedy — though in some cases, association-level advocacy or litigation has resulted in broader MAC methodology changes.

For policy denials, review the provider manual carefully. If the PBM is citing a policy basis for denial that is not actually present in the agreement you signed, the appeal can be elevated and often succeeds.

Dispensing decisions when MAC rates are below cost

Independent pharmacies facing persistent below-cost MAC reimbursement on specific medications sometimes consider dispensing alternatives. The options are narrow, but they exist.

Therapeutic substitution requires prescriber consent but can move patients to medications with better MAC economics where clinically appropriate. Filling in smaller quantities can reduce per-claim exposure, though it shifts the cost structure to different areas. Declining to dispense — directing the patient to a pharmacy that can fulfill at the plan's terms — is a last-resort option that some independent pharmacies use for medications where below-cost reimbursement is persistent and the appeal process has been exhausted.

Building MAC appeal into operations

Pharmacies that handle MAC appeals well generally share three practices. They run a weekly or biweekly review of claims flagged as below acquisition cost. They maintain a standard appeal template and documentation checklist that makes submission fast. And they track appeal outcomes by PBM, which over time reveals which PBMs are more or less receptive to which types of documentation — information that makes future appeals more efficient.

The appeal process is not intended to be adversarial. But treating it with the same operational discipline as other reimbursement-protection activities is what separates pharmacies that capture available remedies from those that lose margin to below-cost MAC rates on every eligible claim.